AOD-9604 Overview
Mechanism of Action
AOD-9604 is a modified fragment of human growth hormone (hGH 177-191) with a tyrosine substitution. It retains the lipolytic activity of GH without growth-promoting or diabetogenic effects. Stimulates lipolysis and inhibits lipogenesis via beta-3 adrenergic receptor pathways.
~30–45 minutes
Timing
Morning on empty stomach or before bed
Injection Site
Subcutaneous, abdomen
Food
Fast 2+ hours before
Common Stacks
- MOTS-c — Complementary metabolic pathways
- 5-Amino-1MQ — Synergistic fat metabolism
- CJC-1295/Ipamorelin — Full GH support + lipolysis
AOD-9604 Dosing Protocol
Standard Protocol
12 weeks250–500 mcg SQ daily
On empty stomach, preferably morning.
Enhanced Protocol
8–12 weeks500 mcg SQ daily
Can split 250 mcg AM + 250 mcg pre-bed.
AOD-9604 Expected Timeline
Week 1–2
Subtle metabolic changes
Week 3–4
Enhanced fat mobilization
Week 6–8
Measurable fat reduction
Week 8–12
Significant body composition improvements
AOD-9604 Side Effects
Headache (mild, transient)
Injection site irritation
Generally well tolerated
AOD-9604 Research Studies
AOD9604: A novel anti-obesity drug candidate
Heffernan MA, Thorburn AW, Fam B, et al. — Obesity (2001)
Demonstrated AOD-9604 significantly reduced body fat in obese mice without affecting IGF-1 levels or inducing diabetogenic effects.
PubMed: 11331428AOD-9604 FAQ
Does AOD-9604 affect growth or IGF-1?
No. AOD-9604 isolates the fat-metabolizing portion of GH, providing lipolytic benefits without growth effects.
Should AOD-9604 be taken with food?
No. Take on an empty stomach. Carbohydrates and insulin spikes blunt the fat-mobilizing effects.